Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIP 
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANIP (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $95.5
1 Year Target Price $95.5
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.26% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.01B USD | Price to earnings Ratio - | 1Y Target Price 95.5 |
Price to earnings Ratio - | 1Y Target Price 95.5 | ||
Volume (30-day avg) 6 | Beta 0.61 | 52 Weeks Range 52.50 - 93.72 | Updated Date 08/28/2025 |
52 Weeks Range 52.50 - 93.72 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate 1.4 | Actual 1.8 |
Profitability
Profit Margin -1.37% | Operating Margin (TTM) 7.18% |
Management Effectiveness
Return on Assets (TTM) 1.09% | Return on Equity (TTM) -2.17% |
Valuation
Trailing PE - | Forward PE 12.95 | Enterprise Value 2415661371 | Price to Sales(TTM) 2.69 |
Enterprise Value 2415661371 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 3.23 | Enterprise Value to EBITDA 27.13 | Shares Outstanding 21688800 | Shares Floating 16989125 |
Shares Outstanding 21688800 | Shares Floating 16989125 | ||
Percent Insiders 10.45 | Percent Institutions 97.83 |
Upturn AI SWOT
ANI Pharmaceuticals Inc
Company Overview
History and Background
ANI Pharmaceuticals, Inc. was founded in 2003 and has grown through strategic acquisitions and product development. It focuses on manufacturing and marketing generic and branded pharmaceuticals, primarily serving niche markets. A significant milestone was its expansion into contract manufacturing.
Core Business Areas
- Generic Pharmaceuticals: Development, manufacturing, and marketing of generic pharmaceutical products across a range of therapeutic areas.
- Branded Pharmaceuticals: Marketing and sales of branded pharmaceutical products, often targeting specialized or niche markets.
- Contract Manufacturing: Providing contract manufacturing services to other pharmaceutical companies.
Leadership and Structure
The company is led by a management team with experience in the pharmaceutical industry. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Erythromycin and Isosorbide Mononitrate: A combination drug used to treat certain heart conditions. Market share data unavailable. Competitors include other generic manufacturers of similar medications.
- Various Oral Solid Dose Generics: A portfolio of various generic drugs in tablet and capsule form. Market share data unavailable as the company's business is focused on niche generics. Competitors include other generic manufacturers such as Teva and Mylan (Viatris).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high regulation, intense competition, and constant innovation. Generic drug manufacturers face pricing pressure and consolidation, while branded drug companies rely on patents and marketing to maintain market share.
Positioning
ANI Pharmaceuticals positions itself as a niche player focusing on specialized generics and branded products where competition is limited. Its competitive advantage lies in its manufacturing capabilities and ability to acquire and develop niche products.
Total Addressable Market (TAM)
The total addressable market for generic pharmaceuticals is in the hundreds of billions of dollars globally. ANI focuses on smaller, more specialized segments within this larger market, positioning itself to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Specialized manufacturing capabilities
- Niche market focus
- Acquisition strategy
- Strong cash flow generation
Weaknesses
- Reliance on acquisitions for growth
- Limited R&D pipeline compared to larger companies
- Exposure to pricing pressure in generic market
- Smaller size compared to major competitors
Opportunities
- Further acquisitions of complementary products or companies
- Expansion into new therapeutic areas
- Increased demand for generic drugs
- Partnerships and collaborations with other pharmaceutical companies
Threats
- Increased competition from larger generic manufacturers
- Regulatory changes impacting drug pricing or approval processes
- Patent challenges on branded products
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ENDP
Competitive Landscape
ANI Pharmaceuticals Inc competes with both large generic manufacturers and smaller niche players. Its advantage lies in its focus on specialized products and its manufacturing capabilities.
Major Acquisitions
Alimera Sciences
- Year: 2024
- Acquisition Price (USD millions): 82.5
- Strategic Rationale: Expands ANI Pharmaceuticals' portfolio with ILUVIEN, a non-hormonal, sustained-release intravitreal implant to treat diabetic macular edema (DME).
Growth Trajectory and Initiatives
Historical Growth: ANI Pharmaceuticals Inc's historical growth has been driven by acquisitions and organic growth of its existing product portfolio.
Future Projections: Future growth projections require access to analyst estimates and company guidance.
Recent Initiatives: Recent initiatives include acquisitions of new products and expansion of manufacturing capabilities.
Summary
ANI Pharmaceuticals is a niche pharmaceutical company with strengths in specialized manufacturing and strategic acquisitions. The company's focus on niche generics and branded products allows it to compete in less crowded markets. However, it faces challenges from larger competitors and regulatory changes, requiring continuous innovation and efficient management of its product portfolio. Acquisitions continue to drive growth for the company and must continue to execute on identifying and integrating these in the future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.